Daily Roundup

RUL.ASX MIN.ASX TLS.ASX NEU.ASX REA.ASX

Rpmglobal Holdings Ltd Extends Share Buy-back Program

RPMGlobal Holdings Limited (ASX: RUL) has announced the extension of its current on-market share buy-back program for an additional 12 months. The company plans to buy back up to 11 million shares, representing around 5% of its total issued capital. RPM has already bought back 17 million shares worth $32 million through the program since it commenced last year. The Board believes this ongoing capital management strategy aligns with the company's current and historical share price, as well as its available cash position of $80.5 million.

Mineral Resources Revises Onslow Iron Guidance

Mineral Resources Limited (ASX: MIN) has provided an update on its Onslow Iron project, revising the volume guidance to 7.8-8.0 million tonnes, down from the previous 8.5-8.7 million tonnes. This adjustment is due to lower-than-expected contractor road train availability and daily cycles. However, the project is seeing a strong ramp-up, with 1.7 million tonnes shipped in May and an expected 2.3-2.6 million tonnes to be shipped in June, equivalent to a run rate of 28-31 million tonnes per annum. Mineral Resources remains on track to achieve Onslow Iron's nameplate capacity of 35 million tonnes per annum in the first quarter of fiscal year 2026.

Telstra Unveils Connected Future 30 Strategy

Telstra Group Ltd (ASX: TLS) has announced its Connected Future 30 Strategy, outlining its plans to drive innovation, digital transformation, and enhance customer experience and connectivity over the next three decades. The strategy includes investments in next-generation technologies, such as 5G and fiber-optic networks, to improve network reliability and coverage. Telstra is also focused on expanding its digital capabilities and offerings to better serve its customers' evolving needs. The company is confident that this long-term strategy will position Telstra for sustainable growth, improved operational efficiency, and enhanced shareholder value.

Neuren Pharmaceuticals Delivers Record Financial Results

Neuren Pharmaceuticals Ltd (ASX: NEU) has reported record financial performance in 2024, with A$445 million in royalties from DAYBUE sales. The company also achieved positive Phase 2 trial results for its drug candidate NNZ-2591 in Phelan-McDermid, Pitt Hopkins, and Angelman syndromes, and has aligned with the FDA on the Phase 3 trial design for Phelan-McDermid syndrome. Neuren is in a strong financial position, with A$341 million in cash, and is eager to commence the Phase 3 trial for Phelan-McDermid syndrome and seek alignment with the FDA on the registration path for other indications.

REA Group Responds to ACCC Investigation

REA Group Ltd (ASX: REA) has received a s155 Notice from the Australian Competition and Consumer Commission (ACCC), requiring the company to provide information regarding certain subscription offerings. REA Group remains committed to providing choice, value, and flexibility to its customers and consumers, and is cooperating fully with the ACCC investigation. The company continues to focus on delivering products and services that improve the property experience for buyers, sellers, and renters.